[go: up one dir, main page]

WO2000050595A3 - Nucleic acid molecules associated with melanoma and thyroid tumors - Google Patents

Nucleic acid molecules associated with melanoma and thyroid tumors Download PDF

Info

Publication number
WO2000050595A3
WO2000050595A3 PCT/US2000/004929 US0004929W WO0050595A3 WO 2000050595 A3 WO2000050595 A3 WO 2000050595A3 US 0004929 W US0004929 W US 0004929W WO 0050595 A3 WO0050595 A3 WO 0050595A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
melanoma
thyroid tumors
molecules associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/004929
Other languages
French (fr)
Other versions
WO2000050595A2 (en
Inventor
Ivan Gout
Nikolay Rodnin
Valery Filonenko
Genadiy Matsuka
Matthew Scanlan
Lloyd Old
Boris Bilynsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU32462/00A priority Critical patent/AU3246200A/en
Publication of WO2000050595A2 publication Critical patent/WO2000050595A2/en
Publication of WO2000050595A3 publication Critical patent/WO2000050595A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to isolated nucleic acid molecules associated with melanoma or thyroid tumors and compositions derived therefrom. The present invention further relates to methods for diagnosing and treating melanoma, thyroid tumors and other related pathological conditions such as rectal cancer, lung cancer, breast cancer and colon cancer, by employing such nucleic acid molecules and compositions.
PCT/US2000/004929 1999-02-25 2000-02-25 Nucleic acid molecules associated with melanoma and thyroid tumors Ceased WO2000050595A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32462/00A AU3246200A (en) 1999-02-25 2000-02-25 Nucleic acid molecules associated with melanoma and thyroid tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25741799A 1999-02-25 1999-02-25
US09/257,417 1999-02-25

Publications (2)

Publication Number Publication Date
WO2000050595A2 WO2000050595A2 (en) 2000-08-31
WO2000050595A3 true WO2000050595A3 (en) 2001-06-21

Family

ID=22976239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004929 Ceased WO2000050595A2 (en) 1999-02-25 2000-02-25 Nucleic acid molecules associated with melanoma and thyroid tumors

Country Status (2)

Country Link
AU (1) AU3246200A (en)
WO (1) WO2000050595A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001161374A (en) * 1999-12-13 2001-06-19 Akihiro Abe Polynucleotides, polypeptides, cancer therapeutics and vaccines
EP1266225A2 (en) * 2000-03-20 2002-12-18 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of breast cancer
EP1488007A4 (en) 2002-03-13 2006-05-03 Genomic Health Inc Gene expression profiling in biopsied tumor tissues
JP4606879B2 (en) 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Gene expression profiling of EGFR positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2004213871B9 (en) 2003-02-20 2009-09-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
AU2004283068B2 (en) 2003-06-24 2010-03-18 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
ES2651849T3 (en) 2003-07-10 2018-01-30 Genomic Health, Inc. Expression profile and test algorithm for cancer prognosis
DE602004031368D1 (en) 2003-12-23 2011-03-24 Genomic Health Inc UNIVERSAL REPRODUCTION OF FRAGMENTED RNA
ES2636470T3 (en) 2004-04-09 2017-10-05 Genomic Health, Inc. Gene expression markers to predict response to chemotherapy
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
AU2005304878B2 (en) 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
EP1836629B1 (en) 2004-11-05 2020-03-04 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP2242770A2 (en) * 2008-01-07 2010-10-27 Patrys Limited Barb4 target which comprises tata-binding protein-associated factor 15, antibody designated barb4, barb4 related antibodies, and methods of making and using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196307A (en) * 1988-03-29 1993-03-23 The Johns Hopkins University Cloned human centromere autoantigen
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO1999004040A1 (en) * 1997-07-15 1999-01-28 Ludwig Institute For Cancer Research Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196307A (en) * 1988-03-29 1993-03-23 The Johns Hopkins University Cloned human centromere autoantigen
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO1999004040A1 (en) * 1997-07-15 1999-01-28 Ludwig Institute For Cancer Research Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STRAUSBERG ET AL.: "National cancer institute, cancer genome anatomy project (CGAP)", EMBL DATABASE ACC. NO: AI239958, 5 November 1998 (1998-11-05), XP002141437 *
SULLIVAN: "Human hCENP-B gene for centromere autoantigen B", EMBL DATABASE ACC NO: X55039, 2 August 1991 (1991-08-02), XP002141627 *
TÜRECI ET AL.: "The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40", CANCER RESEARCH, vol. 56, 15 October 1996 (1996-10-15), pages 4766 - 4772, XP002141438 *

Also Published As

Publication number Publication date
AU3246200A (en) 2000-09-14
WO2000050595A2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
WO2000050595A3 (en) Nucleic acid molecules associated with melanoma and thyroid tumors
WO2000028090A3 (en) Diagnostic assay for cancer
WO2006105486A3 (en) Novel tumor suppressor gene and compositions and methods for making and using the same
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
GR3023560T3 (en) Analytical tracers for cancer, particularly malignant breast cancer
WO2003053997A3 (en) Methods of increasing endogenous erythropoietin (epo)
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO1999057565A3 (en) Methods for diagnosing and evaluating cancer
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2007009755A8 (en) Compositions and methods for cancer diagnostics comprising pan-cancer markers
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2005023824A3 (en) Methods for inhibiting tumor cell proliferation
EP2431743A3 (en) Cancer specific glycans and use thereof
EP1131461A4 (en) N-TERMINAL SHORTENED HER-2 / NEU-PROTEIN AS INDICATOR FOR CANCER PROGNOSIS
WO2001036685A3 (en) Differential gene expression in cancer
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
WO2002010436A3 (en) Prognostic classification of breast cancer
WO2009153774A3 (en) Compositions and methods for prognosis of ovarian cancer
WO2007056049A3 (en) Molecular profiling of cancer
WO1999028460A3 (en) Molecules interacting with apoptin
FR2875601B1 (en) VIMENTIN PHOSPHORYLEE AS A MARKER OF AGGRESSIVITY AND / OR INVASIVENESS OF TUMORS
EP0943620A3 (en) Betulinic acid derivatives for inhibiting cancer growth
WO2002092837A3 (en) Nucleic and molecule associated with prostate cancer and melanoma immunodetection and immunotherapy
WO2004101762A3 (en) Detection and treatment of cancers of the colon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase